Take in Non-CME Industry Symposia

The ATS encourages Non-CME Industry Symposia in conjunction with the International Conference. All full-conference participants are encouraged to attend these programs.

6:30 to 9:30 p.m.
Loews Philadelphia Hotel: Regency Ballroom AB
A Picture Is Worth 1,000 Words: Diagnostic Techniques in Pulmonary Hypertension
Pulmonary hypertension is uncommon, but by recognizing the symptoms, signs, and patient history, clinicians can be alerted to the possibility of a PH pathology, diagnose it, and manage it. Speakers will review diagnostic modalities, including echocardiography, CT angiography, V/Q scan, and right-heart catheterization, present representative images, and provide expert guidance on deploying these techniques to provide an enhanced understanding of when to use them, what information they yield, and how they differentiate PH pathologies. The symposium will also highlight how appropriate diagnosis is important in selecting appropriate management.

Speaker(s)/Faculty: Chairperson, Victor Tapson, MD, Director, Duke Center for Pulmonary, Vascular Disease, Professor of Medicine in Pulmonary and Critical Care, Duke University School of Medicine, Durham, NC; Faculty Members: Paul R. Forfia, MD, Assistant Professor of Medicine, Medical Director, Pulmonary Hypertension Program, Hospital of the University of Pennsylvania, Philadelphia, PA; Nick Kim, MD, Associate Clinical Professor of Medicine, Program Director, PCCM Fellowship, University of California San Diego School of Medicine, San Diego, CA; Lacey Washington, MD, Associate Professor of Radiology, Department of Radiology, Duke University School of Medicine, Durham, NC; Hunter Champion, MD, PhD, FAHA, Associate Professor of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
Organizer: Bayer HealthCare

6:30 to 9:30 p.m.
Philadelphia Marriott Downtown: Liberty Salon A, B, C
A Multidisciplinary Approach to Personalizing Medicine for Non-Small Cell Lung Cancer
Over the past decade, several clinically relevant and actionable biomarkers have been identified in non-small cell lung cancer. Individualizing treatment for NSCLC based on molecular markers involves routine biomarker testing that requires efficient, coordinated efforts, and continued communication across multiple specialists, including pathologists, pulmonologists, and medical oncologists. This symposium will delve into a multidisciplinary team approach, emphasizing the critical role of the physician acquiring lung biopsies and exploring molecular testing and subsequent personalized treatment plans for patients with advanced NSCLC.

Faculty: Gerard Silvestri, MD, MS, Medical University of South Carolina, Charleston; Pranil Chandra, DO, PathGroup, Nashville, Tenn.; and Corey J. Langer, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia
Organizer: Boehringer Ingelheim Pharmaceuticals, Inc.

6:30 to 9:30 p.m.
Loews Philadelphia Hotel: Millennium Hall
Controversies in PAH: Treatment Goals & Clinical Decision Making
Controversies in PAH: Treatment Goals & Clinical Decision-Making is an ATS dinner symposium offered to ATS registrants on Sunday May 19th from 6:30 PM to 9:30 PM at the Loews Philadelphia Hotel in Philadelphia, Pennsylvania. A faculty of experts in PAH will explore a series of compelling topics in PAH, including the goals of therapy and the role of clinical trials in therapeutic decision-making. The session will provide a forum for faculty to share evolving perspectives, discuss clinical scenarios, and actively engage program participants.

Speaker(s)/Faculty: David Badesch, MD, University of Colorado Health Sciences Center, Aurora, Colorado; Mardi Gomberg-Maitland, MD, MSc, University of Chicago, Chicago, Illinois; Ronald Oudiz, MD, Harbor-UCLA Medical Center, Torrance, California
Organizer: Gilead Sciences, Inc.

6:30 to 9:30 p.m.
Philadelphia Marriott Downtown: Independence Ballroom
Focus on FeNO: Case Study Reception

Organizer: Aerocrine

6:30 to 9:30 p.m.
Courtyard by Marriott Philadelphia Downtown: Grand Ballroom
Improving the Diagnosis and Individualized Treatment of Patients with Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a progressive, debilitating condition, and left untreated will lead to right ventricular failure and death. Due to the non-specific nature of the symptoms, PAH is unfortunately most frequently diagnosed when patients have reached an advanced stage of disease. In order to effectively help identify and manage patients with PAH, health care professionals must be familiar with the current clinical classification, recognize the full array of tests and evaluations necessary for a diagnosis, and understand the therapeutic options, treatment algorithms, and recommended monitoring. This symposium is designed to discuss early diagnosis and individualized treatment and management of PAH.

Speaker(s)/Faculty: James R. Klinger, MD (chair), professor of medicine, Brown University, and medical director, Respiratory Intermediate Care Unit and the Pulmonary Hypertension Center, Rhode Island Hospital, Providence; Tim Lahm, MD, assistant professor of medicine, Division of Pulmonary, Allergy, Critical Care, Occupational, and Sleep Medicine, Indiana University School of Medicine, Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis; Deborah Jo Levine, MD, associate professor, pulmonary disease and critical care medicine, director, Pulmonary Hypertension Clinic, University of Texas Health Science Center School of Medicine, San Antonio
Educational grant support: Actelion Pharmaceuticals US, Inc.
Organizer: The France Foundation

6:30 to 7:30 p.m.
Loews Philadelphia Hotel: Regency Ballroom AB
Advances in Biomarker Testing for Non-Small Cell Lung Cancer
This presentation is an overview of advances in biomarker testing for NSCLC. It reviews the evolution of biomarker-driven cancer therapy, discusses the current guidelines and clinical relevance of biomarker testing in NSCLC, and highlights the practical considerations for successful implementation of biomarker testing in clinical practice.
Organizer: Pfizer Inc.

6:30 to 9:30 p.m.
Philadelphia Marriott Downtown: Liberty Salon A, B, C
Confronting the Challenges of Idiopathic Pulmonary Fibrosis Diagnosis and Management
Idiopathic pulmonary fibrosis is a chronic, progressive fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, limited to the lungs, and increasing in prevalence. It is characterized by progressive worsening of dyspnea and lung function and is associated with a poor prognosis. Today, the median survival after IPF diagnosis is two to five years. The understanding of IPF pathophysiology has progressed over the past decade, and this knowledge is intertwined with the clinical testing of candidate drugs, several of which are in phase III trials. Diagnosis is difficult, beyond the expertise of any one specialty, but has been codified in recent evidence-based international guidelines, which provide a valuable resource for providers who manage patients with IPF.

Speaker(s)/Faculty: Steven D. Nathan, MD (chair), professor of medicine, Virginia Commonwealth University, Richmond; Kevin R. Flaherty, MD, MS, associate professor, pulmonary and critical care medicine, University of Michigan Health System, Ann Arbor; and David J. Lederer, MD, MS, Herbert Irving assistant professor of medicine and epidemiology (in pediatrics), College of Physicians and Surgeons, Columbia University Mailman School of Public Health, Columbia University Medical Center, New York
Educational grant support: Boehringer Ingelheim Pharmaceuticals, Inc.
Organizer: The France Foundation

6:30 to 9:30 p.m.
Loews Philadelphia Hotel: Millennium Hall
Emerging Developments and Insights in Pulmonary Arterial Hypertension: How We Think, How We Practice
Despite significant advances in the science of pulmonary arterial hypertension (PAH), it remains a debilitating, fatal disease. During this symposium, insights and emerging developments surrounding PAH management will be discussed by an expert panel, as will scientific advances and implications for clinical practice, with audience participation throughout.

Dinner will be provided; however, dinner will not be provided to physicians and other healthcare professionals licensed in Vermont or other states where gifts and meals are prohibited

Organizer: Actelion Pharmaceuticals US, Inc.